News

The FDA’s Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with

The patent includes claims to the use of the company’s drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and

The DSMB’s review of the efficacy data is still pending. Northwest Biotherapeutics chief technical officer Dr. Marnix Bosch noted the company is pleased with the recommendation of the

The trial met its primary efficacy endpoint by showing a significantly lower ‘Total Combined Rhinitis Score’ (TCRS) when compared with patients who received placebo. The trial also showed

The secure online e-prescribing portal is available to healthcare providers in the US, interested in a clinically validated, peer reviewed, non-pharmacologic alternative to narcotic and NSAID pain medications

Furiex Pharmaceuticals, under its agreement with Takeda, is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan. Takeda Pharmaceutical has submitted

Polycythemia vera a chronic, incurable blood cancer associated with an overproduction of blood cells. Novartis announced that the Phase III study of Jakavi has met its primary endpoint

The FDA approval will allow the company to start its US based Phase III study in adult patients with ADHD, and patient enrollment is expected to start shortly.

TrialCTA is a cloud-based Software-as-a-Service (SaaS) application that helps Clinical Research Organizations (CRO’s), medical device and pharmaceutical companies manage and track the complex, global clinical trial contracts related